Evaluating the impact of MR-guided radiation therapy on cancer treatment outcomes
The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
This study is testing how using a special type of radiation therapy with real-time imaging can improve treatment results and quality of life for adults with cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 8000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | UMC Utrecht Academic / other |
| Drugs / interventions | radiation |
| Locations | 18 sites (Pittsburgh, Pennsylvania and 17 other locations) |
| Trial ID | NCT04075305 on ClinicalTrials.gov |
What this trial studies
The MOMENTUM study is an international registry that collects data on patients undergoing radiation therapy using the MR-Linac technology. This observational cohort study aims to enhance the implementation of MR-guided radiation therapy, which allows for real-time imaging and precision treatment. By gathering technical and clinical data, the study seeks to optimize treatment outcomes, minimize side effects, and improve overall patient survival and quality of life. Participants include cancer patients aged 18 and older who are receiving treatment or imaging on the MR-Linac machine.
Who should consider this trial
Good fit: Ideal candidates are cancer patients aged 18 and older who are scheduled for treatment or imaging on an MR-Linac machine.
Not a fit: Patients with MRI contraindications, such as those who are pregnant or have incompatible metal implants, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved survival rates and reduced side effects for cancer patients undergoing radiation therapy.
How similar studies have performed: Other studies have shown promise with MR-guided radiation therapy, indicating potential for success in this innovative approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac; * Patient provides written, informed consent; * Patient is 18 years old or older. Exclusion Criteria: * MRI exclusion criteria, including * MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.
Where this trial is running
Pittsburgh, Pennsylvania and 17 other locations
- Allegheny Health Network — Pittsburgh, Pennsylvania, United States (Recruiting)
- Md Anderson Cancer Center — Houston, Texas, United States (Recruiting)
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States (Recruiting)
- Austin Health - Olivia Newton-John Cancer Wellness and Research Centre — Melbourne, Australia (Not_yet_recruiting)
- Insitut Jules Bordet — Brussels, Belgium (Not_yet_recruiting)
- Sunnybrook Health Sciences Centre/Odette Cancer Centre — Toronto, Ontario, Canada (Recruiting)
- University Health Network - Princess Margaret Cancer Center — Toronto, Canada (Recruiting)
- Odense Universitetshospital — Odense, Funen, Denmark (Recruiting)
- Universitätsklinikum Tübingen — Tübingen, Germany (Recruiting)
- Università degli Studi di Brescia — Brescia, Italy (Not_yet_recruiting)
- IRCCS Ospedale Sacro Cuore Don Calabria — Negrar, Italy (Recruiting)
- Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital — Amsterdam, Netherlands (Recruiting)
- Radiotherapiegroep — Deventer, Netherlands (Recruiting)
- Radiotherapeutisch Instituut Friesland (RIF) — Leeuwarden, Netherlands (Not_yet_recruiting)
- Radboud UMC — Nijmegen, Netherlands (Recruiting)
- University Medical Center Utrecht — Utrecht, Netherlands (Recruiting)
- The Royal Marsden and The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre — London, United Kingdom (Recruiting)
- The Christie National Health Service Foundation Trust — Manchester, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Helena M Verkooijen, Prof, Dr — Universitair Medical Centre Utrecht
- Study coordinator: Tessa Leer
- Email: T.Leer@umcutrecht.nl
- Phone: T +31 (0)88 75 63707
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.